BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 35039793)

  • 1. Metadichol®: A Novel Nanolipid Formulation That Inhibits SARS-CoV-2 and a Multitude of Pathological Viruses In Vitro.
    Raghavan PR
    Biomed Res Int; 2022; 2022():1558860. PubMed ID: 35039793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
    Li K; Meyerholz DK; Bartlett JA; McCray PB
    mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.
    Hoffmann M; Hofmann-Winkler H; Smith JC; Krüger N; Arora P; Sørensen LK; Søgaard OS; Hasselstrøm JB; Winkler M; Hempel T; Raich L; Olsson S; Danov O; Jonigk D; Yamazoe T; Yamatsuta K; Mizuno H; Ludwig S; Noé F; Kjolby M; Braun A; Sheltzer JM; Pöhlmann S
    EBioMedicine; 2021 Mar; 65():103255. PubMed ID: 33676899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
    Sun G; Sui Y; Zhou Y; Ya J; Yuan C; Jiang L; Huang M
    J Virol; 2021 Sep; 95(19):e0086121. PubMed ID: 34160253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
    Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
    J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner.
    Yamamoto M; Kiso M; Sakai-Tagawa Y; Iwatsuki-Horimoto K; Imai M; Takeda M; Kinoshita N; Ohmagari N; Gohda J; Semba K; Matsuda Z; Kawaguchi Y; Kawaoka Y; Inoue JI
    Viruses; 2020 Jun; 12(6):. PubMed ID: 32532094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of host cell serine protease inhibitor MM3122 against SARS-CoV-2 for treatment and prevention of COVID-19.
    Boon ACM; Bricker TL; Fritch EJ; Leist SR; Gully K; Baric RS; Graham RL; Troan BV; Mahoney M; Janetka JW
    J Virol; 2024 May; 98(5):e0190323. PubMed ID: 38593045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells.
    Mahoney M; Damalanka VC; Tartell MA; Chung DH; Lourenço AL; Pwee D; Mayer Bridwell AE; Hoffmann M; Voss J; Karmakar P; Azouz NP; Klingler AM; Rothlauf PW; Thompson CE; Lee M; Klampfer L; Stallings CL; Rothenberg ME; Pöhlmann S; Whelan SPJ; O'Donoghue AJ; Craik CS; Janetka JW
    Proc Natl Acad Sci U S A; 2021 Oct; 118(43):. PubMed ID: 34635581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of potent small molecule inhibitors of SARS-CoV-2 entry.
    Mediouni S; Mou H; Otsuka Y; Jablonski JA; Adcock RS; Batra L; Chung DH; Rood C; de Vera IMS; Rahaim R; Ullah S; Yu X; Getmanenko YA; Kennedy NM; Wang C; Nguyen TT; Hull M; Chen E; Bannister TD; Baillargeon P; Scampavia L; Farzan M; Valente ST; Spicer TP
    SLAS Discov; 2022 Jan; 27(1):8-19. PubMed ID: 35058179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19.
    Kosinsky Y; Peskov K; Stanski DR; Wetmore D; Vinetz J
    Microbiol Spectr; 2022 Apr; 10(2):e0216721. PubMed ID: 35412356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Clinical-Stage Cysteine Protease Inhibitor blocks SARS-CoV-2 Infection of Human and Monkey Cells.
    Mellott DM; Tseng CT; Drelich A; Fajtová P; Chenna BC; Kostomiris DH; Hsu J; Zhu J; Taylor ZW; Kocurek KI; Tat V; Katzfuss A; Li L; Giardini MA; Skinner D; Hirata K; Yoon MC; Beck S; Carlin AF; Clark AE; Beretta L; Maneval D; Hook V; Frueh F; Hurst BL; Wang H; Raushel FM; O'Donoghue AJ; de Siqueira-Neto JL; Meek TD; McKerrow JH
    ACS Chem Biol; 2021 Apr; 16(4):642-650. PubMed ID: 33787221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection.
    Wettstein L; Weil T; Conzelmann C; Müller JA; Groß R; Hirschenberger M; Seidel A; Klute S; Zech F; Prelli Bozzo C; Preising N; Fois G; Lochbaum R; Knaff PM; Mailänder V; Ständker L; Thal DR; Schumann C; Stenger S; Kleger A; Lochnit G; Mayer B; Ruiz-Blanco YB; Hoffmann M; Sparrer KMJ; Pöhlmann S; Sanchez-Garcia E; Kirchhoff F; Frick M; Münch J
    Nat Commun; 2021 Mar; 12(1):1726. PubMed ID: 33741941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.
    Essalmani R; Jain J; Susan-Resiga D; Andréo U; Evagelidis A; Derbali RM; Huynh DN; Dallaire F; Laporte M; Delpal A; Sutto-Ortiz P; Coutard B; Mapa C; Wilcoxen K; Decroly E; Nq Pham T; Cohen ÉA; Seidah NG
    J Virol; 2022 Apr; 96(8):e0012822. PubMed ID: 35343766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical TMPRSS2 inhibition prevents SARS-CoV-2 infection in differentiated human airway cultures.
    Guo W; Porter LM; Crozier TW; Coates M; Jha A; McKie M; Nathan JA; Lehner PJ; Greenwood EJ; McCaughan F
    Life Sci Alliance; 2022 Apr; 5(4):. PubMed ID: 35110354
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Huang ST; Chen Y; Chang WC; Chen HF; Lai HC; Lin YC; Wang WJ; Wang YC; Yang CS; Wang SC; Hung MC
    Viruses; 2021 May; 13(5):. PubMed ID: 34063247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
    Lee J; Lee J; Kim HJ; Ko M; Jee Y; Kim S
    Microbiol Spectr; 2021 Sep; 9(1):e0047221. PubMed ID: 34378968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
    Hoffmann M; Kleine-Weber H; Schroeder S; Krüger N; Herrler T; Erichsen S; Schiergens TS; Herrler G; Wu NH; Nitsche A; Müller MA; Drosten C; Pöhlmann S
    Cell; 2020 Apr; 181(2):271-280.e8. PubMed ID: 32142651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TMPRSS11D and TMPRSS13 Activate the SARS-CoV-2 Spike Protein.
    Kishimoto M; Uemura K; Sanaki T; Sato A; Hall WW; Kariwa H; Orba Y; Sawa H; Sasaki M
    Viruses; 2021 Feb; 13(3):. PubMed ID: 33671076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the intestinal TMPRSS2 protease to prevent SARS-CoV-2 entry into enterocytes-prospects and challenges.
    Mahmoud IS; Jarrar YB
    Mol Biol Rep; 2021 May; 48(5):4667-4675. PubMed ID: 34023987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protease inhibitors targeting coronavirus and filovirus entry.
    Zhou Y; Vedantham P; Lu K; Agudelo J; Carrion R; Nunneley JW; Barnard D; Pöhlmann S; McKerrow JH; Renslo AR; Simmons G
    Antiviral Res; 2015 Apr; 116():76-84. PubMed ID: 25666761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.